Novo Nordisk reveals positive Ozempic kidney results

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo. Around 40% of people with type 2 diabetes have chronic kidney disease. It stopped the trials on 3,533 people a full year before it was mean ...